A routine medication change led to an unexpected medical discovery when a woman developed a rare inflammatory skin condition shortly after starting a new inhaler. The case is drawing attention among healthcare professionals because it may represent one of the first documented links between an inhaled respiratory medication and Sweet syndrome.

The patient, a 55-year-old woman with a history of chronic obstructive pulmonary disease (COPD) and hypertension, had long managed her condition successfully with established treatments. However, after a decline in lung function, her physician adjusted her respiratory therapy and prescribed a new inhaler containing a combination of bronchodilator medications.

Within just 48 hours of beginning the new treatment, she noticed the sudden appearance of painful, bright red patches across her face and neck. She also experienced a mild fever, prompting immediate medical evaluation.

Concerned by the rapid onset of symptoms, her healthcare team referred her for urgent dermatological assessment. The inhaler was discontinued as a precaution while specialists investigated the cause.

Extensive testing ruled out infections, allergic reactions, and autoimmune disorders. A skin biopsy ultimately confirmed the diagnosis: Sweet syndrome, a rare inflammatory condition also known as acute febrile neutrophilic dermatosis.